BioTime Inc (BTX)

3.18
AMEX : Health Care
Prev Close 3.15
Day Low/High 3.06 / 3.19
52 Wk Low/High 2.25 / 4.00
Avg Volume 338.10K
Exchange AMEX
Shares Outstanding 110.88M
Market Cap 349.26M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime's Renevia® Achieves Primary Endpoint In European Pivotal Trial

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that, based on the analysis of top line data, the Renevia®...

BioTime To Announce Top Line Data From The Company's Renevia European Pivotal Trial

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company's...

BioTime Co-CEO Dr. Michael West To Deliver Presentation As Part Of Biotech Panel At Mauldin Economics' Strategic Investment Conference On May 24

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

BioTime Presents Retinal Restoration Data At ARVO

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the Company's retinal restoration...

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the first quarter ended...

BioTime Announces New Positive Data From OpRegen® Trial In Dry-AMD

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial...

BioTime Co-CEO Dr. Michael D. West To Present At World Advanced Therapies & Regenerative Medicine Congress On May 17 And 19

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

BioTime, Inc. To Announce First Quarter 2017 Results On May 10, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating...

BioTime To Present Additional Data At Upcoming ARVO

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company's retinal tissue...

BioTime Forms New Subsidiary AgeX Therapeutics, Inc. To Develop Its Programs Focused On Human Aging

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the formation of AgeX Therapeutics, Inc.

BioTime Co-CEO Dr. Michael West To Deliver Keynote Presentation At GTC Bio Stem Cell Summit On April 6

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

Key BioTime Patents Upheld By European Patent Office

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before...

BioTime To Present At Oppenheimer 27th Annual Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be...

BioTime, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the fourth quarter and year...

Data From BioTime's OpRegen® Trial In Dry-AMD To Be Presented At ARVO On May 8

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase...

BioTime Expands OpRegen® Clinical Trial In Dry-AMD With Opening Of First US Sites

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for...

BioTime, Inc. To Announce Fourth Quarter And Fiscal 2016 Results On March 16, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial...

BioTime Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten...

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be...

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock...

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., As General Counsel

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana Patton, Ph.

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement For Next-Generation Retinal Disease Therapy From University Of Pittsburgh Medical Center

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related...

BioTime To Present At Noble Capital Markets' Thirteenth Annual Investor Conference

BioTime To Present At Noble Capital Markets' Thirteenth Annual Investor Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the...

Additional Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ARVO 2017

Additional Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ARVO 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd.

BioTime And Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center In Jerusalem, Israel

BioTime And Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center In Jerusalem, Israel

BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences...